<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523484</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-OKR-CAS-2007/1</org_study_id>
    <nct_id>NCT00523484</nct_id>
  </id_info>
  <brief_title>Casodex/Zoladex Hormonal therApy Study for assessMent of Correlation Between PSA &amp; BAI in prOstate Cancer patieNts</brief_title>
  <acronym>CHAMPION</acronym>
  <official_title>An Observational Study to Assess Correlation Between Prostate Specific Antigen &amp; Beck Anxiety Index in Prostate Cancer Patients Under Hormonal Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an observational study to see whether anxiety level can be correlated with PSA
      level under the current practice in the patients of prostate cancer taking hormonal therapy.
      For assessment of anxiety level BAI(Beck Anxiety Inventory) will be used. The target
      population for this study is the patients of prostate cancer diagnosed previously and who are
      taking hormonal therapy with regular follow-up and PSA test. The follow-up duration will be
      total 6 months with interim visit at 3 month and final visit at 6 month.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced prostate cancer patients who were being treated by hormonal agents
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of written informed consent

          2. Patients who take PSA test regularly

          3. Observation suitable patients for PSA change according to hormonal treatment at least
             for 6months

          4. Locally advanced or advanced prostate cancer patients who is suitable for hormonal
             therapy

          5. Prostate Cancer Patients who has been taking one treatment among 3 hormonal therapies
             in below:

               -  Bicalutamide Monotherapy : Bicalutamide 150mg/day

               -  Goserelin 3.6mg/10.8mg

               -  MAB(Maximal Androgen Blockade) :Bicalutamide 50mg + Goserelin 3.6/10.8mg

        Exclusion Criteria:

          1. Prohibition use under permitted indication

          2. Previous inclusion in the present study

          3. Participation in a clinical study during the last 30 days
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miyoung Kim</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyunggi</city>
        <state>Anyang-si Dongan-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <state>Jongro-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Democratic People's Republic of</country>
  </removed_countries>
  <link>
    <url>http://www.astrazeneca.com/node/emailtriage.aspx</url>
  </link>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2007</study_first_submitted>
  <study_first_submitted_qc>August 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2007</study_first_posted>
  <last_update_submitted>January 25, 2010</last_update_submitted>
  <last_update_submitted_qc>January 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>MC CD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Beck Anxiety Inventory</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Prostate Specific Antigen</keyword>
  <keyword>Naturalistic</keyword>
  <keyword>Observational</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

